[Exploration and Challenge of Whole Course Follow-up Management Model 
for Small Cell Lung Cancer].

Chengming Huang, Yongzhao Zhou, Jing Xu, Wenting Lu, Li Tu, Yalun Li, Panwen Tian
{"title":"[Exploration and Challenge of Whole Course Follow-up Management Model \u2029for Small Cell Lung Cancer].","authors":"Chengming Huang, Yongzhao Zhou, Jing Xu, Wenting Lu, Li Tu, Yalun Li, Panwen Tian","doi":"10.3779/j.issn.1009-3419.2025.106.01","DOIUrl":null,"url":null,"abstract":"<p><p>Small cell lung cancer (SCLC) is a highly malignant disease that has garnered significant attention in terms of treatment modalities and course management. Gaining an understanding of the clinical characteristics of SCLC, acquiring proficiency in screening, diagnosis, and treatment methods for this condition, as well as promptly addressing any adverse reactions to treatment are essential foundations for developing a scientific and rational pathological management plan for SCLC. By utilizing an intelligent whole course follow-up management platform, dynamic follow-up, timely warnings, and early interventions can enable high-quality whole life cycle management. This article aims to review the current treatment landscape of SCLC while exploring the challenges associated with implementing a comprehensive process-oriented management approach. The goal is to provide valuable insights for better managing SCLC patients and ultimately improving their quality of life and prognosis.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 1","pages":"47-54"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11848691/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国肺癌杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3779/j.issn.1009-3419.2025.106.01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Small cell lung cancer (SCLC) is a highly malignant disease that has garnered significant attention in terms of treatment modalities and course management. Gaining an understanding of the clinical characteristics of SCLC, acquiring proficiency in screening, diagnosis, and treatment methods for this condition, as well as promptly addressing any adverse reactions to treatment are essential foundations for developing a scientific and rational pathological management plan for SCLC. By utilizing an intelligent whole course follow-up management platform, dynamic follow-up, timely warnings, and early interventions can enable high-quality whole life cycle management. This article aims to review the current treatment landscape of SCLC while exploring the challenges associated with implementing a comprehensive process-oriented management approach. The goal is to provide valuable insights for better managing SCLC patients and ultimately improving their quality of life and prognosis.
.

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[小细胞肺癌全程随访管理模式
的探索与挑战]。
小细胞肺癌(SCLC)是一种高度恶性的疾病,在治疗方式和病程管理方面引起了极大的关注。了解SCLC的临床特点,熟练掌握SCLC的筛查、诊断和治疗方法,及时处理治疗后的不良反应,是制定科学合理的SCLC病理管理方案的重要基础。通过智能全程随访管理平台,动态随访、及时预警、早期干预,实现高质量的全生命周期管理。本文旨在回顾当前SCLC的治疗情况,同时探讨与实施全面的面向过程的管理方法相关的挑战。目标是为更好地管理SCLC患者并最终改善他们的生活质量和预后提供有价值的见解。
。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
中国肺癌杂志
中国肺癌杂志 Medicine-Pulmonary and Respiratory Medicine
CiteScore
1.40
自引率
0.00%
发文量
5131
审稿时长
14 weeks
期刊介绍: Chinese Journal of Lung Cancer(CJLC, pISSN 1009-3419, eISSN 1999-6187), a monthly Open Access journal, is hosted by Chinese Anti-Cancer Association, Chinese Antituberculosis Association, Tianjin Medical University General Hospital. CJLC was indexed in DOAJ, EMBASE/SCOPUS, Chemical Abstract(CA), CSA-Biological Science, HINARI, EBSCO-CINAHL,CABI Abstract, Global Health, CNKI, etc. Editor-in-Chief: Professor Qinghua ZHOU.
期刊最新文献
[China National Lung Cancer Screening Guideline with Low-dose Computed Tomography (2025 Version)]. [Efficacy and Safety of High-dose Furmonertinib plus Intrathecal Pemetrexed 
for EGFR-mutant Non-small Cell Lung Cancer with Leptomeningeal Metastasis]. [Clinical Characteristics and Prognosis Analysis of Thoracic SMARCA4-deficient
Undifferentiated Tumor versus SMARCA4-deficient Non-small Cell Lung Cancer]. [Identification of SORD as A Key Gene Mediating Osimertinib Primary Resistance 
in EGFR-Mutant Lung Adenocarcinoma via Machine Learning and Methylomics]. [Ensartinib Combined with Radiotherapy for the Treatment of Advanced Primary 
Pulmonary Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring 
TPM3-ALK Fusion: A Case Report].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1